基于遗传数据仓库对疑似DPYD变异携带者进行确认性检测
本研究探索利用机构遗传数据仓库识别疑似携带可干预基因型的患者,在氟尿嘧啶化疗前进行确认性DPYD检测的可行性。项目实施2年内被动监测约3000名疑似DPYD携带者,以极小成本和努力阻止了1名确认携带者接受毒性过高的氟尿嘧啶治疗。该策略在监管和技术上可行,可扩展至其他基因和药物。
要点
- 利用研究性遗传数据被动识别疑似DPYD携带者,在用药前确认检测可行。
- 2年内监测约3000名疑似携带者,1名确认携带者避免氟尿嘧啶毒性治疗。
- 该实施流程成本低、效率高,可推广至其他证据充分的基因-药物对。
核心结论
- 利用机构遗传数据仓库识别疑似可干预基因型携带者并在用药前确认检测,在监管和技术上可行且高效。
研究设计与样本
- 基于单机构遗传数据仓库的可行性实施研究,以氟尿嘧啶化疗前DPYD检测为案例。
主要发现
- 项目启动2年内被动监测约3000名疑似DPYD携带者。
- 1名确认DPYD携带者被阻止接受毒性过高的氟尿嘧啶治疗。
- 实施成本与投入极小。
临床怎么用
- 对研究性遗传数据中疑似可干预基因型携带者,在处方相关药物前进行确认性PGx检测。
- 可计划过渡至PGx panel检测并扩展至其他证据充分但常规检测不足的基因-药物对。
局限性
- 为单机构可行性案例,未报告确认检测总数、灵敏度或成本的具体数值。
- 策略依赖已有研究性遗传数据仓库,其他机构可探索性需另行评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Using pharmacogenetics (PGx) to inform clinical decision making can benefit patients but clinical use of PGx testing has been limited. Existing genetics data obtained in the course of research could be used to identify patients who are suspected, but have not yet been confirmed, to carry clinically actionable genotypes, in whom confirmatory genetic testing could be conducted for highly efficient PGx implementation. Herein, we demonstrate that it is regulatorily and technically feasible to implement PGx by identifying suspected carriers of actionable genotypes within an institutional genetics data repository and conduct confirmatory PGx testing immediately prior to that patient receiving the PGx-relevant drug, using a case study of DPYD testing prior to fluoropyrimidine chemotherapy. In 2 years since launching this program, ~ 3,000 suspected DPYD carriers have been passively monitored and one confirmed DPYD carrier was prevented from receiving unacceptably toxic fluoropyrimidine treatment, for minimal cost and effort. Now that we have demonstrated the feasibility of this strategy, we plan to transition to PGx panel testing and expand implementation to other genes and drugs for which the evidence of clinical benefit of PGx-informed treatment is high but PGx testing is not generally conducted. This highly efficient implementation process will maximize the clinical benefits of testing and could be explored at other institutions that have research-only genetic data repositories to expand the number of patients who benefit from PGx-informed treatment while we continue to work toward wide-scale adoption of PGx testing and implementation.
引用
- Pasternak AL, Seda R, Lipa J, et al. Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository. Clin Pharmacol Ther. 2023. PMID: 37163252. doi:10.1002/cpt.2936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。